Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer | Zendy

Aditya Bardia | Zendy; Sara A. Hurvitz | Zendy; Sara M. Tolaney | Zendy; Delphine Loirat | Zendy; Kevin Punie | Zendy; Mafalda Oliveira | Zendy; Adam Brufsky | Zendy; Sagar Sardesai | Zendy; Kevin Kalinsky | Zendy; Amelia Zelnak | Zendy; Robert Weaver | Zendy; Tiffany A. Traina | Zendy; Florence Dalenc | Zendy; Philippe Aftimos | Zendy; Filipa Lynce | Zendy; Sami Diab | Zendy; Javier Cortés | Zendy; Joyce O’Shaughnessy | Zendy; Véronique Dièras | Zendy; Cristiano Ferrario | Zendy; Peter Schmid | Zendy; Lisa A. Carey | Zendy; Luca Gianni | Zendy; Martine Piccart | Zendy; Sibylle Loibl | Zendy; David M. Goldenberg | Zendy; Quan Hong | Zendy; Martin Olivo | Zendy; Loretta M. Itri | Zendy; Hope S. Rugo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Author(s) -

Aditya Bardia,

Sara A. Hurvitz,

Sara M. Tolaney,

Delphine Loirat,

Kevin Punie,

Mafalda Oliveira,

Adam Brufsky,

Sagar Sardesai,

Kevin Kalinsky,

Amelia Zelnak,

Robert Weaver,

Tiffany A. Traina,

Florence Dalenc,

Philippe Aftimos,

Filipa Lynce,

Sami Diab,

Javier Cortés,

Joyce O’Shaughnessy,

Véronique Dièras,

Cristiano Ferrario,

Peter Schmid,

Lisa A. Carey,

Luca Gianni,

Martine Piccart,

Sibylle Loibl,

David M. Goldenberg,

Quan Hong,

Martin Olivo,

Loretta M. Itri,

Hope S. Rugo

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2028485

Subject(s) - medicine , hazard ratio , vinorelbine , metastatic breast cancer , oncology , breast cancer , chemotherapy , eribulin , gemcitabine , cancer , gastroenterology , surgery , confidence interval , cisplatin

Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the majority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) through a proprietary hydrolyzable linker.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research